Quantitative analysis for Hemab Therapeutics Holdings, Inc. Common Stock (COAG) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (42.0) (grade D). 28 signals analyzed (23 differentiated alt-data).
COAG stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-05-01 | $36.61 | $27.00 | $34.00 |
| 2026-05-13 | $28.65 | $25.40 | $28.56 |
| 2026-05-26 | $28.00 | $26.75 | $27.84 |
| 2026-06-05 | $26.40 | $24.50 | $25.30 |
| 2026-06-17 | $27.95 | $25.42 | $26.45 |
| 2026-06-30 | $38.22 | $35.11 | $36.73 |
| 2026-07-13 | $42.03 | $37.99 | $39.51 |
| 2026-07-23 | $49.90 | $45.64 | $45.83 |
| 2026-08-04 | $49.48 | $45.23 | $46.52 |
| 2026-08-17 | $55.18 | $51.77 | $53.59 |
| 2026-08-27 | $51.11 | $48.61 | $49.49 |
How Hemab Therapeutics Holdings, Inc. Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| CUE | Cue Biopharma, Inc. | $54M | — |
| ELUT | Elutia Inc. | $52M | — |
| NRXP | NRx Pharmaceuticals, Inc. | $51M | — |
| ACRV | Acrivon Therapeutics, Inc. Common Stock | $56M | — |
View all Health Care stocks by valuation and signals →
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) scores Sell (42.0), and the composite conceals a 61-point disagreement between its dimensions. It is strongest on analyst consensus at 88, and weakest on competitive moat at 27. A stock can carry analyst consensus that high while competitive moat sits at 27; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 88 |
| technicals | 44 |
| competitive moat | 27 |
StoQuant analyzes 28 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Hemab Therapeutics Holdings, Inc. Common Stock (COAG): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/COAG"><img src="https://stoquant.com/badge/COAG.svg" alt="Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.